Abstract
BackgroundHepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population. Some studies have shown that adding Sofosbuvir (SOF), an HCV polymerase inhibitor to the conventional therapy of Pegylated-interferon (PegIFN) plus Ribavirin (RBV) can increase the rate of sustained virologic response (SVR) among HCV-infected patients. This study was conducted to determine the effect of combination therapy with PegIFN and RBV plus SOF for chronic hepatitis C genotype 1 infection using systematic review with meta-analysis.MethodsIn this study, electronic databases including PubMed, Scopus, Science Direct, and Web of Science were comprehensively searched using appropriate strategies containing all related keywords of “hepatitis C”, “PegIFN”, “RBV” and “SOF”. Studies assessed the efficacy of combination therapy with PegIFN and RBV plus SOF for chronic hepatitis C genotype 1 infection were included in the meta-analysis.ResultsAfter screening of 757 records, we included five articles with total sample size of 411 to the meta-analysis. Based on the fixed-effect model (χ2 = 5.29, P = 0.26 and I2 = 24.4%), pooled SVR rate for treatment regimen of PegIFN and RBV plus SOF was calculated as 88.54% (95% CI = 85.77%–91.32%).ConclusionsCombination therapy with PegIFN and RBV plus SOF results in high treatment response in patients with HCV genotype 1 infection.
Highlights
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population
Based on the World Health Organization (WHO) estimation, about 3% of world population is infected with hepatitis C virus (HCV) and the worldwide prevalence of chronic hepatitis C is more than 180 million who are at the predisposing to cirrhosis and/or liver cancer [1,2,3]
Four of our included studies were from the United States and another one was from Germany
Summary
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population. Some studies have shown that adding Sofosbuvir (SOF), an HCV polymerase inhibitor to the conventional therapy of Pegylated-interferon (PegIFN) plus Ribavirin (RBV) can increase the rate of sustained virologic response (SVR) among HCV-infected patients. This study was conducted to determine the effect of combination therapy with PegIFN and RBV plus SOF for chronic hepatitis C genotype 1 infection using systematic review with meta-analysis. Based on the World Health Organization (WHO) estimation, about 3% of world population is infected with hepatitis C virus (HCV) and the worldwide prevalence of chronic hepatitis C is more than 180 million who are at the predisposing to cirrhosis and/or liver cancer [1,2,3]. Adding Ribavirin (RBV) to Pegylated-interferon (PegIFN) increased SVR rate from 15 to 20% to 40%–50% in HCV genotype 1 infection. To reach to more than 50% SVR, combination therapy with PegIFN and RBV lost its efficacy in HCV genotype 1 infection [6,7,8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
